炎症性疾患男性患者の精子と性ホルモンに対するフィルゴチニブの影響: フェーズ2, 無作為化, 二重盲検, プラセボ対照 マンタおよびマンタレイ試験
Ann Rheum Dis 2023;82:1049–1058
Reinisch, et al. show that filgotinib treatment has no effect on semen parameters for men with active inflammatory diseases. This contrasts with pre-clinical studies that showed fertility issues in male animals.
Men with active inflammatory diseases were treated with filgotinib for 13 weeks in MANTA and MANTA-RAy. These two trials were multinational, randomised, double-blind, placebo-controlled, parallel-group, phase 2 studies.
Keywords:
